Table 1.

Demographics and baseline clinical characteristics

Demographic parameterDose escalation (Part 1; n = 39)Dose expansion (Part 2; n = 71)Overall (N = 110)
Median age, years (range)58.0 (19–81)57.0 (18–88)57.0 (18–88)
Male, n (%)6 (15.4)28 (39.4)34 (30.9)
ECOG performance status, n (%)
 023 (59.0)37 (52.1)60 (54.5)
 116 (41.0)34 (47.9)50 (45.5)
Tumor type, n (%)
 Breast8 (20.5)12 (16.9)20 (18.2)
 Ovarian/peritoneal23 (59.0)11 (15.5)34 (30.9)
 Prostate1 (2.6)3 (4.2)4 (3.6)
 Pancreatic3 (7.7)10 (14.1)13 (11.8)
 Ewing sarcoma2 (5.1)12 (16.9)14 (12.7)
 SCLC023 (32.4)23 (20.9)
 Colorectal2 (5.1)02 (1.8)
Deleterious mutation, n (%)
 gBRCA116 (41.0)13 (18.3)29 (26.4)
 gBRCA27 (17.9)20 (28.2)27 (24.5)
 gBRCA1/21 (2.6)2 (2.8)3 (2.7)
Median prior chemotherapy regimens, n (range)4.0 (1.0–13.0)2.0 (0.0–6.0)2.5 (0.0–13.0)
Median prior platinum regimens, n (range)2.0 (0.0–4.0)1.0 (0.0–4.0)1.0 (0.0–4.0)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; gBRCA, germline BRCA mutated.